Comparison of G-CSF and GM-CSF adverse event profiles in office-based practices: preliminary study results.
We investigated the adverse event profile of colony-stimulating factors (CSFs) used in office-based oncology practices in the United States. The impetus for the study was anecdotal reports from physicians and nurses working in community practice settings describing the differences in adverse drug events (ADEs) that their-patients experienced with the two CSFs currently available in the United States. The study was a retrospective review of office-based oncology practice records. The frequencies of drug-induced fever and other ADEs secondary to granulocyte (G)-CSF were compared with those of granulocyte-macrophage (GM)-CSF. Adverse drug events were those events that were documented by a clinician as being causally linked to CSF therapy and not obviously due to other causes. This preliminary report of the data indicated that there were some significant differences in the ADEs attributable to either G-CSF or GM-CSF. The appropriate use of CSFs in clinical practice also is discussed.
Moleski
R J
RJ
RJM Associates, Inc., Guilford, Connecticut 06437, USA.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced*; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D011994:Recombinant Proteins; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor